SELECT Trial Shows Semaglutide 2.4 mg Could Reduce Cardiovas

Novo Nordisk has announced topline data from the SELECT trial, which suggest use of once-weekly semaglutide 2.4 mg was associated with a statistically significant 20% reduction in 3-point MACE among a cohort with overweight or obesity and established cardiovascular disease.

Related Keywords

Martin Holst Lange , Drug Administration , Development At Novo Nordisk , Novo Nordisk , Select Trial , Semaglutide 2 4 Mg , Wegovy , Semaglutide 2 4 Mg Wegovy , Cardiology , Major Adverse Cardiovascular Events ,